Evaluation of Activated Platelet Rich Plasma Versus Non-Activated Platelet Rich Plasma in Alopecia Areata
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Hair length in group A
研究概览
简要总结
This was comparative prospective study conducted on 40 subjects, diagnosed with alopecia areata of 40 the scalp, carried in a period from February 2020 and March 2021
详细描述
Alopecia areata is a common recurrent T cell-mediated autoimmune-induced non-scarring hair loss with not fully understood pathogenesis which affects nearly 2% of the general population during lifetime. The course of the disease is unpredictable and currently, no treatment is available for complete cure or prevention. Platelet-rich plasma is an autologous blood-derived product which widely spread in the last decades for the treatment of different dermatological conditions including different hair disorders.
The aim of this work was to evaluate the efficacy and safety of activated platelet-rich plasma in comparison to non-activated platelet-rich plasma in the treatment of alopecia areata.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients diagnosed clinically and dermatoscopically as Alopecia areata of the scalp (uni- or 50 multilocularis).
- •Age ranged between 18-50 years in both sex.
- •Exclusion criteria:
- •Previously treated patients.
- •Pregnant women. 3 Patients with hematological disorders.
- •Local infection at the site.
- •Patients with Hemoglobin <10 g/dL and Platelet count <105/µL.
- •Patients suffer from chronic and psychiatric diseases. 7.Age below 18years or age above 50 years ago.
排除标准
- 未提供
研究组 & 干预措施
Activated plasma rich in platelets
Group A: patients were treated by intradermal injections of PRP activated with Calcium chloride 10% solution.
干预措施: Intradermal injection (Drug)
Non- activated plasma rich in platelets
Group B: patients were treated by intradermal injections of PRP without activation.
干预措施: Intradermal injection (Drug)
结局指标
主要结局
Hair length in group A
时间窗: three months
PRP as treatment option was in indicating its anti-inflammatory properties. 183 PRP effective in AA through anti-inflammatory mechanisms owing to its ability to suppress Monocyte 184 chemotactic protein-1 and owing to the presence of Transforming growth factor (β1 and β2) as was 185 shown by Amable and El-Sharkavy with coauthors
次要结局
- Hair length in Group B(five months)
研究者
Ahmed Hassan Nouh MD
Principal Investigator
Al-Azhar University